Nanobiotix SA

As of December 31, 2025, Nanobiotix SA carries a market capitalization of 929.05M, placing it among publicly traded companies globally. Its enterprise value stands at 971.62M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Nanobiotix SA's next confirmed earnings release is scheduled for April 27, 2027.

As of December 31, 2025, Nanobiotix SA has 48.39M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Nanobiotix SA maintains a current ratio of 1.09, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Nanobiotix SA's stock has gained approximately 18.01% over the past 52 weeks. The 50-day moving average sits at 29.32, while the 200-day moving average is 29.00.

As of December 31, 2025, Nanobiotix SA holds 52.75M in cash and equivalents against 95.32M in total debt, resulting in a net debt position of 39.47M. Total book value stands at -84.48M, with working capital of 5.24M providing operational flexibility.

Nanobiotix SA's most recent stock split took place on February 25, 2014.